Matrix Global Advisors Report Reveals Key Lessons for the United States from Europe’s Biosimilar Experience

Wednesday June 3, 2020

WASHINGTON, DC (JUNE 3, 2020) — A new report from Matrix Global Advisors (MGA) details “lessons learned” from the European biosimilars experience that can improve access to these medicines for America’s patients.

MGA found that “there are important ways that the U.S. market should depart from Europe’s experience in order to better foster competition” and that European policies like price setting and tender systems “would prove detrimental to the long-term sustainability of the US biosimilars market.” However, MGA noted there are lessons from the European experience U.S. stakeholders should strive to follow as the market enters its second decade, including collaborative education campaigns and incentives for their use.

“Today’s report makes clear stakeholder alignment in encouraging the uptake of biosimilars through adoption incentives and widespread education efforts was key to early European market success,” says Christine Simmon, Executive Director, Biosimilars Council, and Senior Vice President of Policy and Strategic Alliances, AAM. “Across the spectrum, U.S. stakeholders must work together to ensure the viability of the marketplace through policies that promote biosimilar adoption and uptake.”

MGA highlighted an important step in encouraging a vibrant biosimilars marketplace: “Decision-makers across the [U.S.] healthcare system, including government programs, should push biosimilar uptake by setting utilization targets and creating incentives for uptake by sharing biosimilar savings with providers and patients.” The report also challenged the conventional wisdom that the European biosimilars market is flourishing while the U.S. market lags behind, noting that “it is time to move beyond this outdated perception.”



Rachel Schwartz


About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About Matrix Global Advisors

Matrix Global Advisors, led by CEO and Founder Alex Brill and Principal Christy Robinson, is an economic policy consulting firm in Washington, DC, that specializes in fiscal, health care, and tax policy matters. Drawing on years of policy experience, the MGA team uses analytics to help identify, quantify, and solve economic policy problems. On behalf of clients, we conduct original data analysis, construct economic models, conduct research, write white papers and expert reports, and offer strategic advice.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



Register Now! February 5–7, 2024 | Tampa, Florida

AAM’s annual meeting Access! 2024 brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Discussions center around the business, breakthroughs and politics that shape our industry. It’s the opportunity to hear firsthand from world-renowned speakers and learn about where our industry is heading and what our future holds.